Reaction
Incorrect Product Formulation Administered reporting signals
As of the last recalculation, Incorrect Product Formulation Administered appears in 831 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is GALCANEZUMAB-GNLM (PRR 86.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Galcanezumab-Gnlm | 96 | 86.2 | 86.4 |
| Sodium Chloride Tablet | 63 | 23.1 | 23.1 |
| Sodium Chloride Tablets | 63 | 23.1 | 23.1 |
| Sodium Chloride | 63 | 21.5 | 21.5 |
| Insulin Lispro | 101 | 20.7 | 20.7 |
| Onabotulinumtoxina | 54 | 18.7 | 18.7 |
| Insulin Human | 24 | 15.5 | 15.6 |
| Iohexol | 5 | 15.2 | 15.2 |
| Dulaglutide | 27 | 7.8 | 7.9 |
| Tirzepatide | 47 | 7.7 | 7.7 |
| Rimegepant Sulfate | 3 | 5.9 | 5.9 |
| Ixekizumab | 7 | 4.8 | 4.8 |